Table 1. Patient enrollment process.
| Characteristics | Value |
|---|---|
| Age (y) | 56.3 ± 15.6 (range, 22–81) |
| Sex | |
| Men:Women | 34 (65.4%):18 (34.6%) |
| Underlying liver disease | |
| None | 29 (55.8%) |
| HBV | 16 (30.8%) |
| HCV | 3 (5.8%) |
| Alcohol + HBV | 2 (3.8%) |
| Alcohol | 1 (1.9%) |
| Non-alcoholic steatohepatitis | 1 (1.9%) |
| Liver cirrhosis | |
| Presence | 16 (30.8%) |
| Absence | 36 (69.2%) |
| Lesion size (cm) | 3.5 ± 2.5 (range, 1–14) |
| Final Diagnosis | |
| HCC | 19 (36.5%) |
| Non-HCC malignancies | 13 (25.0%) |
| Metastasis from other primary malignancy | 12 (23.1%) |
| Colorectal cancer | 4 (7.7%) |
| Pancreatic cancer | 3 (5.8%) |
| Breast cancer | 1 (1.9%) |
| Gallbladder cancer | 1 (1.9%) |
| Gastrointestinal stromal tumor | 1 (1.9%) |
| Intrahepatic cholangiocarcinoma | 1 (1.9%) |
| Perihilar cholangiocarcinoma | 1 (1.9%) |
| Diffuse large B-cell lymphoma | 1 (1.9%) |
| Benign lesions | 20 (38.5%) |
| FNH | 8 (15.4%) |
| Hemangioma | 5 (9.6%) |
| Hepatocellular adenoma | 2 (3.8%) |
| Angiomyolipoma | 2 (3.8%) |
| Abscess | 2 (3.8%) |
| Intrahepatic reactive lymphoid hyperplasia | 1 (1.9%) |
| Standard of reference | |
| Pathologic diagnosis | 34 (65.4%) |
| Noninvasive diagnosis of HCC | 9 (17.3%) |
| Typical imaging features of hemangioma (n = 5) and FNH (n = 4) on CECT or MRI | 9 (17.3%) |
Note.—HBV = Hepatitis B virus; HCV = Hepatitis C virus; HCC = hepatocellular carcinoma; FNH = Focal nodular hyperplasia; CECT = contrast-enhanced CT.